A current type of diabetes drugs can help cancer patients repel the risk of heart failure by 50 and increase long -term recovery, according to new research on Thursday.

Heart insufficiency is common in cancer patients and can lead to a reduction in quality of life, multiple admissions to the hospital or even to death. It is caused both due to the deadly disease due to chemotherapy – the first line of cancer treatment.

Researchers from the University of East Anglia in the United Kingdom have shown that a type of diabetes medication – an SGLT2 inhibitor – can help protect the heart during and after cancer treatment.

The study, published in the European Journal of Preventive Cardiology, has shown that SGLT2 inhibitors can reduce the risk of heart failure and unforeseen hospital visits linked to heart failure of more than 50%.

The advantages were particularly promising for patients with breast cancer, said the chemotherapy team. “Chemotherapy has played an instrumental role in improving the results of patients.

But up to 20 patients with cancer who have had chemotherapy to develop heart problems, up to 10 suffering from heart failure,” said the principal researcher, Professor Vassilios Vassiliou, of the university.

“We know that SGLT2 inhibitors are recognized for their cardiovascular advantages. They can improve the symptoms of heart failure such as shortness of breath and fatigue, and also reduce the risk of becoming fragile,” added Vassiliou.

To see if SGLT2 inhibitors could help protect the heart during and after cancer treatment, the team analyzed 13 studies with a total of 88,273 patients with cancer and survivors. The team found that admissions to the hospital for heart failure had been reduced by half.

The number of new cases of heart failure seemed to be more than two thirds (71), which suggests that these pills could help protect the heart during and after the treatment of cancer. However, researchers noted that more research is necessary to confirm the results.

Source

https://news.google.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?hl=en-IN&gl=IN&ceid=IN%3Aen